A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to
determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal
biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety,
tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered
intravenously to subjects with advanced solid tumors.